Literature DB >> 36216484

Renoprotective Effects of SGLT2 Inhibitors.

Volker Vallon1.   

Abstract

SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption. This improves cortical oxygenation, which, together with lesser tubular glucotoxicity and improved mitochondrial function and autophagy, can reduce proinflammatory and profibrotic signaling and preserve tubular function and GFR in long term. By shifting transport downstream, SGLT2 inhibitors may mimic systemic hypoxia and stimulate erythropoiesis, which improves oxygen delivery to the kidney and other organs.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Diabetic nephropathy; Hyperfiltration; Proximal tubule; SGLT2 inhibitor; Tubuloglomerular feedback

Mesh:

Substances:

Year:  2022        PMID: 36216484      PMCID: PMC9558099          DOI: 10.1016/j.hfc.2022.03.005

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   2.828


  98 in total

1.  SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Authors:  Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

2.  Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

Authors:  Hassan Rahmoune; Paul W Thompson; Joanna M Ward; Chari D Smith; Guizhu Hong; John Brown
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.

Authors:  Jens Jordan; Jens Tank; Karsten Heusser; Tim Heise; Christoph Wanner; Martina Heer; Sreeraj Macha; Michaela Mattheus; Søren S Lund; Hans J Woerle; Uli C Broedl
Journal:  J Am Soc Hypertens       Date:  2017-07-21

4.  SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.

Authors:  Issei Tomita; Shinji Kume; Sho Sugahara; Norihisa Osawa; Kosuke Yamahara; Mako Yasuda-Yamahara; Naoko Takeda; Masami Chin-Kanasaki; Tatsuroh Kaneko; Eric Mayoux; Michael Mark; Motoko Yanagita; Hisakazu Ogita; Shin-Ichi Araki; Hiroshi Maegawa
Journal:  Cell Metab       Date:  2020-07-28       Impact factor: 27.287

5.  Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.

Authors:  Hiddo J L Heerspink; Mehul Desai; Meg Jardine; Dainius Balis; Gary Meininger; Vlado Perkovic
Journal:  J Am Soc Nephrol       Date:  2016-08-18       Impact factor: 10.121

6.  Regulation of the human Na+-dependent glucose cotransporter hSGLT2.

Authors:  Chiara Ghezzi; Ernest M Wright
Journal:  Am J Physiol Cell Physiol       Date:  2012-06-06       Impact factor: 4.249

7.  Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.

Authors:  Volker Vallon; Michael Rose; Maria Gerasimova; Joseph Satriano; Kenneth A Platt; Hermann Koepsell; Robyn Cunard; Kumar Sharma; Scott C Thomson; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2012-11-14

8.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Authors:  Brendon L Neuen; Tamara Young; Hiddo J L Heerspink; Bruce Neal; Vlado Perkovic; Laurent Billot; Kenneth W Mahaffey; David M Charytan; David C Wheeler; Clare Arnott; Severine Bompoint; Adeera Levin; Meg J Jardine
Journal:  Lancet Diabetes Endocrinol       Date:  2019-09-05       Impact factor: 32.069

9.  Possible mechanism of efferent arteriole (Ef-Art) tubuloglomerular feedback.

Authors:  Y Ren; J L Garvin; R Liu; O A Carretero
Journal:  Kidney Int       Date:  2007-03-07       Impact factor: 10.612

10.  Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.

Authors:  Susumu Takagi; Jinpeng Li; Yuta Takagaki; Munehiro Kitada; Kyoko Nitta; Toshiyuki Takasu; Keizo Kanasaki; Daisuke Koya
Journal:  J Diabetes Investig       Date:  2018-03-12       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.